Sermorelin vs Ipamorelin
Peptide Schedule Research TeamReviewed Apr 202612 Citations
Side-by-side comparison of dosage, benefits, and side effects.
Twenty-nine amino acids. That's what separates the sermorelin peptide (also known as Geref or GRF 1-29) from the full 44-amino-acid endogenous GHRH molecule, and those 29 amino acids are the only ones that matter for receptor binding. Sermorelin acetate (CAS 86168-78-7) is a synthetic analog of human GHRH(1-29)NH2 that retains complete GHRH receptor affinity on pituitary somatotroph cells. The mechanism is direct. Sermorelin binds the GHRH receptor, triggering pulsatile GH release that mirrors the body's natural secretion pattern. Unlike exogenous growth hormone injections, this preserves the hypothalamic-pituitary feedback loop. The pituitary decides how much GH to release; sermorelin just gives it a stronger signal to do so. That distinction matters for long-term safety. Vittone and colleagues ran a six-month trial in age-advanced adults (PMID 9141536) using once-daily subcutaneous GHRH analog injections. The results landed on lean mass gains, fat reduction, and improved sleep architecture. The Geref International Study Group (PMID 8772599) confirmed sustained growth velocity in GH-deficient children at 30 mcg/kg/day over 12 to 36 months. Subcutaneous bioavailability sits at approximately 6% per the Geref product label, which is expected for GHRH analogs and still produces reliable pharmacological GH pulses. In practice, sermorelin is the "start here" peptide on r/Peptides (roughly 95,000 subscribers). Community dosing runs 200 to 300 mcg nightly, almost always co-injected with ipamorelin for dual-pathway GH release. Sleep improvement within the first two weeks is the most consistently reported early effect across hundreds of threads. Body composition shifts require two to three months of patience. No new large RCTs for anti-aging indications have been published between 2024 and 2026, so the adult off-label evidence base relies on the 1990s clinical data combined with a large, consistent community experience.
View full guide →Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998, PMID 9849822) explains why ipamorelin became the default starter peptide for growth hormone optimization. Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Human pharmacokinetic modeling by Svensson et al. (1999, PMID 10496658) confirmed a 2-hour half-life, roughly 95% subcutaneous bioavailability, and a dose-response ceiling around 300 to 400 mcg per injection. Going higher doesn't produce a bigger pulse. The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a synergistic GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response. Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only finished human RCT (Phase 2b for postoperative ileus) failed its primary endpoint versus placebo. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Andersen et al. 1999, PMID 10828840) and cachexia (2024 ferret model, PMID 39043357) looks promising but hasn't been replicated in humans.
View full guide →At a Glance
| Attribute |   Sermorelin |   Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Safety Grade | B | A |
| Half-Life | ~10-20 min | ~2 hours |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5mg | 2mg, 5mg |
| Beginner Dose | 200mcg Daily | 100mcg Daily |
| Moderate Dose | 300mcg Daily | 200mcg 2x Daily |
| Aggressive Dose | 500mcg Daily | 300mcg 3x Daily |
| Dosing Source | Community | Community |
| Side Effects | Antibody formation is the primary long-term safety concern with sermorelin. The Geref prescribing information documents that approximately 70% of patients on continuous daily dosing develop anti-sermorelin antibodies by 18 months. These antibodies neutralize the peptide and progressively reduce its ability to stimulate GH release. This isn't a minor footnote. Users who skip cycling and run sermorelin continuously for six-plus months commonly report complete loss of effect. The antibody response is antigen-driven, so reducing injection frequency (5 days on, 2 days off) and taking periodic four-week breaks are the established mitigation strategies. Facial flushing is the most common acute side effect. It typically occurs 20 to 30 minutes after injection and results from the vasodilatory response to acute GH release. Community reports and clinical data both describe this as transient, resolving within an hour, and most prominent during the first one to three weeks of use. It does not require dose adjustment unless severe. Headache and dizziness post-injection are reported at moderate frequency. Like flushing, these relate to the acute GH pulse. They tend to resolve by weeks three to four without intervention. If persistent, reducing the dose by 50 mcg usually handles it. Injection-site reactions (redness, minor irritation, occasional nodules) are expected with any subcutaneous peptide. Consistent site rotation and allowing refrigerated peptide to reach room temperature before injecting both reduce incidence. Nodules persisting beyond one week warrant switching to a different anatomical region. GH-mediated insulin resistance is a theoretical concern with any GH-raising therapy. Sermorelin produces physiological (not supraphysiological) GH pulses, so the risk is lower than with exogenous GH. Still, fasting glucose monitoring every three months is appropriate, especially for anyone over 40 or carrying metabolic risk factors. A fasting glucose above 126 mg/dL means stopping. GH promotes cell proliferation. Active cancer, a history of malignancy, or active pituitary tumors are absolute contraindications. If IGF-1 surpasses the age-adjusted upper normal range, the dose should be reduced or the protocol discontinued. Untreated hypothyroidism impairs GH response to sermorelin (Geref contraindications). GH also accelerates T4-to-T3 conversion, so thyroid function may shift during use. Baseline thyroid panel is recommended. Pregnancy and breastfeeding are contraindicated. Effects on fetal development have not been established. When to see a doctor: persistent edema, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, symptoms of intracranial hypertension, or any sign of glucose intolerance. | The most serious risk with ipamorelin is IGF-1 overshoot. Sustained supraphysiological IGF-1 levels carry a theoretical cancer promotion risk, particularly in anyone with active malignancy or a history of cancer. GH promotes cell proliferation. That's the mechanism behind its benefits and its biggest concern. If IGF-1 climbs above the age-adjusted upper normal range on two consecutive readings, the protocol should stop. Carpal tunnel symptoms (tingling or numbness in the hands) are the clearest signal that GH levels have gone too high. Community reports flag this primarily at the aggressive tier (300 mcg three times daily). This isn't a "push through it" side effect. Tingling means stop immediately, wait at least four weeks, and restart at a lower dose and frequency if appropriate. Water retention is common, especially at twice-daily or three-times-daily dosing. Mild puffiness around the face or ankles is the typical presentation. Reducing injection frequency (not dose) is the first adjustment. Transient headache within 30 to 60 minutes of injection is expected and relates directly to the acute GH pulse. It resolves within hours for most users. Cutting the dose by 25% usually handles persistent headache. Injection-site reactions (mild redness, irritation) are reported frequently in the first two weeks and tend to resolve with consistent site rotation. Abdomen is the preferred injection location. Occasional lightheadedness immediately post-injection is reported but typically mild. Published side effect data in humans is limited. The only completed human RCT (Phase 2b, postoperative ileus, approximately 100 participants) recorded adverse events but focused on GI recovery endpoints rather than the subcutaneous anti-aging use case. Community side-effect reporting across hundreds of threads is remarkably consistent, which provides reasonable confidence in the profile above, but formal incidence rates don't exist for the off-label application. GH release antagonizes insulin action. Fasting glucose should be monitored at baseline, week six, and week twelve. Anyone with uncontrolled diabetes or severe insulin resistance should not use ipamorelin. A fasting glucose above 126 mg/dL means discontinuation. Pregnancy and breastfeeding are contraindicated due to insufficient safety data. GH supplementation can also unmask subclinical hypothyroidism by accelerating T4-to-T3 conversion; thyroid monitoring (TSH, fT3) is recommended at baseline. When to see a doctor: persistent hand tingling or numbness, significant edema, fasting glucose above 126 mg/dL, any visual changes, or symptoms of intracranial hypertension. |
Key Differences
- Sermorelin is a GHRH analog that amplifies natural growth hormone pulses. Ipamorelin is a ghrelin mimetic (GHRP) that triggers GH release through a different receptor. They work through separate pathways.
- Ipamorelin is the cleanest GHRP available. It does not raise cortisol, prolactin, or appetite at normal doses. Sermorelin has minimal side effects but can cause antibody formation over 6+ months of use.
- Sermorelin requires daily injection. Ipamorelin can be dosed 1 to 3 times daily depending on goals, with a 2-hour half-life allowing flexible timing.
- Sermorelin has a narrower dose range (200 to 500 mcg daily). Ipamorelin spans 100 to 300 mcg per injection, with frequency being the main variable.
- Most practitioners recommend stacking these rather than choosing one. The GHRH + GHRP combination produces a stronger, cleaner GH pulse than either peptide alone.
When to Choose Sermorelin
- You want a single daily injection for GH optimization
- Sleep quality and deep sleep improvement are the main goals
- You're already on a GHRP and want to switch to a GHRH instead
- You prefer the simplest possible dosing protocol (one injection at bedtime)
When to Choose Ipamorelin
- Clean GH release without cortisol or prolactin spikes matters most
- Fat loss and body composition are primary goals
- You want precise control with flexible dosing (1 to 3 times daily)
- You're looking for the safest entry point into GH peptides (safety grade A)
Can You Stack Sermorelin + Ipamorelin?
Sermorelin + ipamorelin is one of the most popular GH peptide stacks. Sermorelin primes the GHRH receptor while ipamorelin triggers release through the ghrelin receptor. Together they produce a stronger, more natural GH pulse than either peptide alone. Inject both subcutaneously at the same time, typically before bed.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Frequently Asked Questions
Not medical advice. Talk to your provider before using any peptide.
Full disclaimer